Public Health Ontariogrid.415400.4, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Torontogrid.17063.33, Toronto, Ontario, Canada.
Microbiol Spectr. 2022 Feb 23;10(1):e0068121. doi: 10.1128/spectrum.00681-21. Epub 2022 Feb 16.
The N501Y amino acid mutation caused by a single point substitution A23063T in the spike gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is possessed by three variants of concern (VOCs), B.1.1.7, B.1.351, and P.1. A rapid screening tool using this mutation is important for surveillance during the coronavirus disease 2019 (COVID-19) pandemic. We developed and validated a single nucleotide polymorphism real-time reverse transcription PCR assay using allelic discrimination of the spike gene N501Y mutation to screen for potential variants of concern and differentiate them from SARS-CoV-2 lineages without the N501Y mutation. A total of 160 clinical specimens positive for SARS-CoV-2 were characterized as mutant (N501Y) or N501 wild type by Sanger sequencing and were subsequently tested with the N501Y single nucleotide polymorphism real-time reverse transcriptase PCR assay. Our assay, compared to Sanger sequencing for single nucleotide polymorphism detection, demonstrated positive percent agreement of 100% for all 57 specimens displaying the N501Y mutation, which were confirmed by Sanger sequencing to be typed as A23063T, including one specimen with mixed signal for wild type and mutant. Negative percent agreement was 100% in all 103 specimens typed as N501 wild type, with A23063 identified as wild type by Sanger sequencing. The identification of circulating SARS-CoV-2 lineages carrying an N501Y mutation is critical for surveillance purposes. Current identification methods rely primarily on Sanger sequencing or whole-genome sequencing, which are time consuming, labor intensive, and costly. The assay described herein is an efficient tool for high-volume specimen screening for SARS-CoV-2 VOCs and for selecting specimens for confirmatory Sanger or whole-genome sequencing. During the coronavirus disease 2019 (COVID-19) pandemic, several variants of concern (VOCs) have been detected, for example, B.1.1.7, B.1.351, P.1, and B.1.617.2. The VOCs pose a threat to public health efforts to control the spread of the virus. As such, surveillance and monitoring of these VOCs is of the utmost importance. Our real-time RT-PCR assay helps with surveillance by providing an easy method to quickly survey SARS-CoV-2 specimens for VOCs carrying the N501Y single nucleotide polymorphism (SNP). Samples that test positive for the N501Y mutation in the spike gene with our assay can be sequenced to identify the lineage. Thus, our assay helps to focus surveillance efforts and decrease turnaround times.
N501Y 氨基酸突变是由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)刺突基因中的单点取代 A23063T 引起的,存在于三种关注变体(VOC)中,即 B.1.1.7、B.1.351 和 P.1。在 2019 年冠状病毒病(COVID-19)大流行期间,使用该突变的快速筛选工具对于监测至关重要。我们开发并验证了一种单核苷酸多态性实时逆转录 PCR 检测方法,该方法利用刺突基因 N501Y 突变的等位基因鉴别来筛选潜在的关注变体,并将其与不具有 N501Y 突变的 SARS-CoV-2 谱系区分开来。总共对 160 份 SARS-CoV-2 阳性临床标本进行了特征分析,通过 Sanger 测序确定为突变(N501Y)或 N501 野生型,随后用 N501Y 单核苷酸多态性实时逆转录酶 PCR 检测方法进行了检测。与用于单核苷酸多态性检测的 Sanger 测序相比,我们的检测方法在所有 57 个显示 N501Y 突变的标本中均表现出 100%的阳性符合率,这些标本通过 Sanger 测序证实被分型为 A23063T,包括一个混合信号的野生型和突变型标本。在所有 103 个被分型为 N501 野生型的标本中,阴性符合率为 100%,Sanger 测序鉴定 A23063 为野生型。识别携带 N501Y 突变的循环 SARS-CoV-2 谱系对于监测目的至关重要。目前的鉴定方法主要依赖于 Sanger 测序或全基因组测序,这些方法耗时、费力且成本高昂。本文所述的检测方法是一种用于高容量 SARS-CoV-2 VOC 标本筛选和选择用于确认 Sanger 或全基因组测序的标本的有效工具。在 2019 年冠状病毒病(COVID-19)大流行期间,已经检测到几种关注变体(VOC),例如 B.1.1.7、B.1.351、P.1 和 B.1.617.2。这些 VOC 对控制病毒传播的公共卫生工作构成威胁。因此,对这些 VOC 的监测和监测至关重要。我们的实时 RT-PCR 检测方法通过提供一种快速检测携带 N501Y 单核苷酸多态性(SNP)的刺突基因的 SARS-CoV-2 样本中的 VOC 的简便方法,有助于监测。用我们的检测方法检测到携带 N501Y 突变的 Spike 基因的样本可以进行测序以鉴定谱系。因此,我们的检测方法有助于集中监测工作并减少周转时间。